Ajai Chari, MD, PhD

Articles

Dr. Chari on Investigational Belantamab Mafodotin Combos in Myeloma

August 20th 2020

Ajai Chari, MD, discusses next steps with belantamab mafodotin-blmf and combination studies in multiple myeloma.

Dr. Chari on Quadruplet Regimens in Transplant-Eligible Multiple Myeloma

November 26th 2019

Ajai Chari, MD, discusses the implementing quadruplet-regimens in transplant-eligible multiple myeloma.

Dr. Chari on Transplant Eligibility in Multiple Myeloma

November 21st 2019

Ajai Chari, MD, discusses transplant eligibility in multiple myeloma.

Dr. Chari on Using Selinexor in Multiple Myeloma Treatment

September 20th 2019

Ajai Chari, MD, discusses the use of selinexor in multiple myeloma treatment.

Dr. Chari on the Use of Frontline Daratumumab in Transplant-Eligible Patients With Myeloma

August 8th 2019

Ajai Chari, MD, associate professor, hematology and medical oncology, Mount Sinai Hospital, discusses the use of frontline daratumumab (Darzalex) in transplant-eligible patients with multiple myeloma.

Dr. Chari on the E3A06 Trial in Smoldering Myeloma

July 29th 2019

Ajai Chari, MD, associate professor, hematology and medical oncology, Mount Sinai Hospital, discusses the phase III E3A06 study, which looked at the effects of lenalidomide in patients with smoldering myeloma.

Dr. Chari on the INSIGHT MM Study on Multiple Myeloma

June 14th 2019

Ajai Chari, MD, Icahn School of Medicine at Mount Sinai, discusses INSIGHT MM (NCT02761187), the largest global, prospective, non-interventional, observational study on multiple myeloma to date.

Dr. Chari Discusses Frail and Elderly Patients With Multiple Myeloma

March 2nd 2019

Ajai Chari, MD, associate professor, Icahn School of Medicine, Mount Sinai Health System, discusses frail and elderly patients with multiple myeloma.

Dr. Chari on Role of Immunotherapy in Myeloma

February 5th 2019

Ajai Chari, MD, associate professor, Icahn School of Medicine, Mount Sinai Health System, discusses the role of immunotherapy in the treatment of patients with myeloma.

Dr. Chari on Treatment of Penta-Refractory Patients With Myeloma

January 19th 2019

Ajai Chari, MD, associate professor, Icahn School of Medicine, Mount Sinai Hospital, discusses the treatment of patients with penta-refractory multiple myeloma.

Dr. Chari on PVd for Relapsed Patients With Multiple Myeloma

December 18th 2018

Ajai Chari, MD, associate professor of Medicine, Hematology and Medical Oncology, at Mount Sinai Hospital, discusses the use of pomalidomide (Pomalyst), bortezomib (Velcade), and dexamethasone (PVd) for relapsed patients with multiple myeloma.

Dr. Chari Discusses Carfilzomib Dosing in Myeloma

December 5th 2018

Ajai Chari, MD, associate professor of medicine, Hematology and Medical Oncology, Mount Sinai Hospital, discusses carfilzomib (Kyprolis) dosing in the treatment of patients with multiple myeloma.

Dr. Chari Discusses the Importance of the ARROW Trial in Myeloma

November 17th 2018

Ajai Chari, MD, associate professor of medicine, Hematology and Medical Oncology, Mount Sinai Hospital, discusses the importance of the ARROW trial in multiple myeloma.

Dr. Chari on Impact of CAR T Cells in Myeloma

November 16th 2018

Ajai Chari, MD, associate professor of medicine, Hematology and Medical Oncology, Mount Sinai Hospital, discusses the impact of CAR T-cell therapy in myeloma.

Dr. Chari on the Subgroup Analysis of MMY1001 in Multiple Myeloma

June 29th 2018

Ajai Chari, MD, associate professor of medicine, Hematology and Medical Oncology, Mount Sinai Hospital, discusses the subgroup analysis of MMY1001 in multiple myeloma.

Dr. Chari on Challenges in Sequencing Agents for Multiple Myeloma

December 14th 2017

Ajai Chari, MD, associate professor, Mount Sinai Hospital, discusses challenges in sequencing agents for patients with multiple myeloma.

Dr. Chari on Comparing Agents in Multiple Myeloma

November 14th 2017

Ajai Chari, MD, associate professor, Mount Sinai Hospital, discusses comparing agents in multiple myeloma.